Aspen Pharmacare's announcement was followed by reassurance from the Africa Centres for Disease Control that it was "doing everything to ensure that those buying vaccines are buying them from Africa".

In March, Aspen signed a deal with Johnson & Johnson to produce 450 million doses per year of its own branded version of a Covid-19 vaccine called Aspenovax.

At the time Aspen’s deal with Johnson & Johnson was called "a game-changer" in providing equitable vaccines to the continent.

The African Union has a target for 60% of all vaccines administered on the continent to be produced locally by 2040. But with only a fifth of Africans vaccinated, that demand has not materialised.

Aspen says it will now be forced to re-purpose some of its production lines to make anaesthetics.